Scarica l'app Stockscreener
8.394
2.21%
0.184
Adma Biologics Inc Borsa (ADMA) Ultime notizie
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
ADMA Biologics Fair Value call saved investors from 40% decline By Investing.com - Investing.com Canada
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on ADMA Biologics, Inc. (ADMA)? Join Class Action Before August 10, 2026Contact Levi & Korsinsky - ACCESS Newswire
Nomura VIP Small Cap Growth Series's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit - The Malaysian Reserve
ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc. - PR Newswire
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - StreetInsider
ADMA Biologics Faces Securities Fraud Lawsuit - Intellectia AI
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire
DEADLINE ALERT for VIA, Z, and ADMA: The Law Offices of - GlobeNewswire
Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
$ADMA Class Action Alert: ADMA Biologics Channel Stuffing - GlobeNewswire
$ADMA Lawsuit: ADMA Biologics Channel Stuffing Allegations Trigger Securities Fraud Class ActionInvestors Notified of August 10 Court Deadline - ACCESS Newswire
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lincolnjournal.com
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - mydailyrecord.com
ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
ADMA Biologics Faces Securities Fraud Lawsuit Amidst Stock Decli - GuruFocus
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
ADMA Faces Securities Fraud Lawsuit Over Alleged Revenue Inflati - GuruFocus
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substan - GuruFocus
ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - Bluefield Daily Telegraph
Law Offices of Howard G. Smith Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - lincolnjournal.com
$ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law - The Malone Telegram
ADMA INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit - The Daily Tribune News
Class Action Lawsuit Filed Against ADMA Biologics - Intellectia AI
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel ... - Caledonian Record
ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block ... - Caledonian Record
ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities - GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ADMA Biologics, Inc. Investors – ADMA - The Joplin Globe
Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21 - Moomoo
ADMA: Analyst Upgrades Stock with $21 Price Target - GuruFocus
Raymond James initiates ADMA Biologics stock coverage with outperform rating - Investing.com Nigeria
ADMA Biologics Investigation: ADMA Biologics (ADMA) - GlobeNewswire
(ADMA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring A 110% Potential Upside In Biotech - DirectorsTalk Interviews
ADMA News | ADMA BIOLOGICS INC (NASDAQ:ADMA) - ChartMill
Assessing ADMA Biologics (ADMA) Valuation After Legal Probes Short Seller Claims And Guidance Withdrawal - Sahm
ASCENIV growth lifts ADMA Biologics (NASDAQ: ADMA) margins and buybacks - Stock Titan
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - ACCESS Newswire
ADMA Biologics earnings on deck amid channel stuffing scrutiny - Investing.com
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Earnings call transcript: ADMA Biologics misses Q1 2026 forecasts, faces competitive pressures - Investing.com
US High Growth Tech Stocks with Promising Potential - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
PFM Health Sciences, LP's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
ADMA Legal Claims: ADMA Biologics may have Misrepresented - GlobeNewswire
ADMA Biologics (ADMA) Is Down 6.7% After FDA Expands ASCENIV Pediatric LabelWhat's Changed - Sahm
ADMA Biologics Shareholders Back Board, Auditor and Pay - TipRanks
ADMA Biologics (ADMA) investors elect directors, ratify KPMG and approve Say-on-Pay - Stock Titan
ADMA Investor News: If You Have Suffered Losses in ADMA - GlobeNewswire
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):